Humana Inc. (NYSE:HUM)‘s stock had its “hold” rating restated by analysts at Cantor Fitzgerald in a research report issued on Friday. They currently have a $225.00 price objective on the insurance provider’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 10.84% from the company’s current price.
The analysts wrote, “Tweaking 4Q16 estimate. We believe 4Q16 consensus EPS of $2.15 (both Bloomberg and FactSet) assumes 1Q16 earnings of $1.86 per share (as we did in our prior estimate of $2.16) versus our revised 4Q16 estimate of $2.04 which is now driven by a 1Q16 diluted EPS of $1.98.””
Several other brokerages have also commented on HUM. Jefferies Group restated a “buy” rating and issued a $230.00 price objective (up from $206.00) on shares of Humana in a report on Thursday, December 1st. Susquehanna reiterated a “neutral” rating and set a $200.00 target price (up from $180.00) on shares of Humana in a report on Sunday, December 4th. Zacks Investment Research lowered shares of Humana from a “buy” rating to a “hold” rating in a report on Monday, December 19th. Piper Jaffray Companies started coverage on shares of Humana in a report on Tuesday, January 3rd. They set an “overweight” rating and a $231.00 target price on the stock. Finally, Credit Suisse Group upgraded shares of Humana from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $175.00 to $210.00 in a report on Friday, November 11th. Seven analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $211.53.
Humana (NYSE:HUM) opened at 202.70 on Friday. The stock has a market capitalization of $30.22 billion, a price-to-earnings ratio of 27.41 and a beta of 0.90. The firm has a 50-day moving average of $204.82 and a 200 day moving average of $182.70. Humana has a 12-month low of $150.00 and a 12-month high of $217.80.
Humana (NYSE:HUM) last issued its quarterly earnings data on Friday, November 4th. The insurance provider reported $3.18 EPS for the quarter, topping the consensus estimate of $3.09 by $0.09. Humana had a net margin of 2.00% and a return on equity of 12.32%. The firm had revenue of $13.69 billion for the quarter, compared to analyst estimates of $13.41 billion. During the same period in the prior year, the business posted $2.16 EPS. The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. On average, analysts predict that Humana will post $9.46 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 27th. Investors of record on Thursday, January 12th will be paid a $0.29 dividend. This represents a $1.16 annualized dividend and a dividend yield of 0.57%. The ex-dividend date is Tuesday, January 10th. Humana’s dividend payout ratio (DPR) is 15.96%.
Several hedge funds have recently made changes to their positions in HUM. LS Investment Advisors LLC boosted its stake in shares of Humana by 1.2% in the second quarter. LS Investment Advisors LLC now owns 5,144 shares of the insurance provider’s stock valued at $925,000 after buying an additional 63 shares during the period. Checchi Capital Advisers LLC increased its position in Humana by 3.1% in the second quarter. Checchi Capital Advisers LLC now owns 2,196 shares of the insurance provider’s stock valued at $395,000 after buying an additional 67 shares during the period. Robeco Institutional Asset Management B.V. increased its position in Humana by 8.0% in the second quarter. Robeco Institutional Asset Management B.V. now owns 11,348 shares of the insurance provider’s stock valued at $2,042,000 after buying an additional 842 shares during the period. Hermes Investment Management Ltd. increased its position in Humana by 8.6% in the second quarter. Hermes Investment Management Ltd. now owns 208,145 shares of the insurance provider’s stock valued at $37,441,000 after buying an additional 16,500 shares during the period. Finally, Oakbrook Investments LLC increased its position in Humana by 14.1% in the second quarter. Oakbrook Investments LLC now owns 9,530 shares of the insurance provider’s stock valued at $1,714,000 after buying an additional 1,175 shares during the period. Hedge funds and other institutional investors own 91.54% of the company’s stock.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group, Healthcare Services and Other Businesses. The Retail segment consists of Medicare benefits, marketed to individuals or directly via group accounts, as well as individual commercial fully-insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
What are top analysts saying about Humana Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Humana Inc. and related companies.